Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dapsone + doxycycline + prednisone
- Development stage
- Preclinical
- Lead developer
- Bayer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy consisting of dapsone (a sulfone drug), doxycycline (a tetracycline antibiotic), and prednisone (a corticosteroid). This combination is used to treat various conditions, particularly relevant for chronic Lyme disease (CLD)/Post-Treatment Lyme Disease Syndrome (PTLDS), pemphigus, and other inflammatory skin conditions like acne vulgaris. It leverages dapsone's anti-inflammatory and antibacterial properties, doxycycline's broad-spectrum antibiotic effects, and prednisone's immunosuppressive and anti-inflammatory actions.
02
Targets
DHPS (Dihydropteroate synthase)Bacterial RibosomeGR (Glucocorticoid receptor)
Beyond the preview
Go deeper on dapsone + doxycycline + prednisone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dapsone + doxycycline + prednisone.